Precision Radiotherapy for Tumours Using Magnetic Resonance-guided Linear Accelerator (MR-Linac)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-08-19

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aim to observe the application of MR-Linac for precision radiotherapy of tumours, analyse its therapeutic effect, toxic and side effects,Characteristics of dosimetric parameters etc.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MR-linac Guided Adaptive Radiotherapy for Inoperable Mediastinal Tumor

NCT05163509

Mediastinal Tumor

UNKNOWN PHASE2

The MR-Linac Technical Feasibility Protocol

NCT04351204

Tumors at All Sites Which Will Receive Radiotherapy

RECRUITING NA

Tumor Response in Hypofractionated Radiotherapy

NCT02854449

Neoplasms

UNKNOWN

Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac

NCT04172753

Rectal Cancer Head and Neck Cancer Liver Cancer +4 more

RECRUITING NA

MRI Development for Radiotherapy Planning and Delivery in Non-Patient Volunteers

NCT04749134

Focus of the Study is MRI Sequence Development

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary endpoint:

· Overall response rate (ORR) : It refers to the proportion of patients whose tumor volume reduction reaches the pre-specified value and can maintain the minimum time requirement, which is a Complete Response (CR) and a partial response (PR). Partial Response) sum of the proportions.

Secondary points:

* Progression-free Survival (PFS) : the time from the start of treatment until objective tumor Progression or all-cause death of the patient.
* Disease Control Rate (DCR) : The percentage of patients whose cancer shrinks or remains stable over time.
* Overall Survival (OS) : the time from the start of treatment to all-cause death.
* Incidence of adverse reactions: toxicity according to Common Toxicity Criteria for Adverse Events (CTCAE).
* Quality of life: The EORTC Quality of Life measure -QLQ-C30-(V3.0) was used, and the higher the score, the higher the quality of life.
* Dosimetric parameters： include gross target volume（GTV）， clinical target volume（CTV），internal target volume(ITV),planning target volume（PTV），γ-passing rate，and limited dose of organs at risk (including average dose, maximum dose, etc.)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overall Response Rate Oncology Radiation Toxicity Quality of Life

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MR-Linac

Radiation therapy with the MR-Linac

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients are undergoing or have undergone imaging or treatment at the MR linac;
* Age 18-75 years, male or female;
* ECOG score 0-2, life expectancy \> 6 months;
* Patients provide written informed consent.

Exclusion Criteria

* Contraindications to MRI, such as claustrophobia and metallic or electronic implants incompatible with MRI;
* The presence of severe comorbidities that, in the opinion of the investigator, · preclude the toleration or completion of radiotherapy;
* Acute inflammatory disease requiring systemic therapy;
* The presence of active infectious disease;
* Pregnant women, nursing mothers, and patients planning to have children during the study period.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No